|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The presence of IL-6 and IL-8 in the arterial wall where complement activation also occurred, clearly show the involvement of inflammatory events in initiation and progression of atherosclerosis.
|
9125317 |
1996 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In apolipoprotein E-null mice, a model for atherosclerosis, levels of BMP-4, HSP70, MGP, and interleukin-6 were elevated in the aortic wall.
|
19661459 |
2009 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Infection with an adenovirus delivering the EMMPRIN-siRNA ameliorated AS, promoted macrophage autophagy in plaques and reduced the serum TNF-α, IL-6, MCP-1 and NF-κB expression levels in the AS mice.
|
29154780 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with those in the NC group, the serum levels of interleukin-6 (IL-6), IL-10, IL-13 and tumor necrosis factor-α (TNF-α) in the AS group significantly increased (p<0.05).
|
31002155 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated that in a large healthy family population, children included, levels of IL-6 are closely associated with traditional and non-traditional atherosclerosis risk factors.
|
14612208 |
2003 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were used to estimate the association between the IL-6 gene -174G>C polymorphism and atherosclerosis ( AS ) risk.
|
23954871 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the relationship of IL-6 and P4Hα1 in atherosclerosis-prone mice and human aortic smooth muscle cells (HASMCs).
|
23022409 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The anti-oxidant <i>N</i>-acetylcysteine (NAC) not only suppresses IL-6 production and VSMC pathological responses including migration and proliferation but also prevents atherosclerosis in <i>ApoE</i><sup>-/-</sup> mice.
|
31817202 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic inflammation due to high IL-6 production occurs in type 2 diabetes (NIDDM) and atherosclerosis.
|
16518702 |
2005 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the Carotid Atherosclerosis Progression Study (CAPS).
|
12574550 |
2003 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease--the Indian Atherosclerosis Research Study.
|
18449426 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 may have a role in aberrant differentiation of VSCs contributing to vascular calcification in atherosclerosis.
|
26840742 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of our study was to investigate the effects of endothelial lipase gene polymorphism and inflammation markers (CRP, IL-1β, IL-6, IL-8 and TNF-α) in the atherosclerosis.
|
23673478 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
As IL-6 increases in atherosclerosis, the study of the polymorphism of IL-6 may be a useful tool in identifying old subjects at risk for atherosclerosis.
|
15050298 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies showed that interleukin 6 (IL-6) has a key role in the pathogenesis of atherosclerosis by binding 2 specific receptors, gp80 and gp130.
|
17472849 |
2007 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study is that ginsenoside Rb1 exerted an inhibitory effect on early atherosclerosis in ApoE-/- mice via decreasing body weight and food intake daily, upregulating the lipid levels of serum plasma, including those of TC, TG and LDL-C and HDL-C and reducing the atherosclerotic plaque area, suppressing inflammatory cytokines (levels of IL-1β, IL-6 and TNF-α) in the serum of ApoE-/- mice, changing the expression levels of BCL-2, BAX, cleaved caspase-3 and cleaved caspase-9 and weakening apoptosis associated with anti-inflammatory activity.
|
30413028 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to explore the relation between abdominal fat distribution and some inflammatory risk factors of atheromatosis and IL-6 174G_C gene polymorphism in non-obese healthy subjects.
|
19569017 |
2009 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis.
|
11116068 |
2000 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate the associations and prognostic value of interleukin-6 (IL6) for the prediction of atherosclerotic cardiovascular disease (ASCVD) events, heart failure (HF), and other chronic diseases in a large, multi-ethnic, contemporary population.
|
30312930 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, our data reveal that in contrast to young MSCs, MSCs from elderly individuals with ATH secrete high levels of IL-6, IL-8/CXCL8 and MCP-1/CCL2 which mediate their reduced immunopotency.
|
28194905 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This could be of importance for the association between cytokines (e.g., IL-6) and insulin resistance and atherosclerosis.
|
12736161 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In CANTOS, the magnitude of benefit of this cytokine-targeted approach to atherosclerosis treatment was associated to the magnitude of reduction of the central signaling cytokine IL-6 and the downstream clinical biomarker high-sensitivity CRP (C-reactive protein).
|
30702995 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously reported that peroxisome proliferator-activated receptor alpha (PPARalpha) ligands (fibrates) lower elevated plasma concentrations of IL-6 in patients with atherosclerosis and inhibit IL-1-stimulated IL-6 secretion by human aortic smooth muscle cells (SMC).
|
10542237 |
1999 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggested that appropriate WBV may delay the progression of AS, which was associated with acutely elevated serum IGF-1 and lower levels of IGF-1 and IL-6 in the aorta for long-term treatment.
|
29707570 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
It can also be protective in CAD patients since the reduced adiponectin-induced IL-6 release in CAD macrophages compared to controls, could be beneficial in the development of inflammation related atherosclerosis.
|
21626471 |
2011 |